128 related articles for article (PubMed ID: 9164923)
1. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.
Tivol EA; Boyd SD; McKeon S; Borriello F; Nickerson P; Strom TB; Sharpe AH
J Immunol; 1997 Jun; 158(11):5091-4. PubMed ID: 9164923
[TBL] [Abstract][Full Text] [Related]
2. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.
Khattri R; Auger JA; Griffin MD; Sharpe AH; Bluestone JA
J Immunol; 1999 May; 162(10):5784-91. PubMed ID: 10229811
[TBL] [Abstract][Full Text] [Related]
3. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.
Bachmann MF; Köhler G; Ecabert B; Mak TW; Kopf M
J Immunol; 1999 Aug; 163(3):1128-31. PubMed ID: 10415006
[TBL] [Abstract][Full Text] [Related]
4. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
Tivol EA; Borriello F; Schweitzer AN; Lynch WP; Bluestone JA; Sharpe AH
Immunity; 1995 Nov; 3(5):541-7. PubMed ID: 7584144
[TBL] [Abstract][Full Text] [Related]
5. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
Mandelbrot DA; McAdam AJ; Sharpe AH
J Exp Med; 1999 Jan; 189(2):435-40. PubMed ID: 9892625
[TBL] [Abstract][Full Text] [Related]
6. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
Zhou T; Weaver C; Linsley PS; Mountz JD
Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
[TBL] [Abstract][Full Text] [Related]
7. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.
Chambers CA; Sullivan TJ; Allison JP
Immunity; 1997 Dec; 7(6):885-95. PubMed ID: 9430233
[TBL] [Abstract][Full Text] [Related]
8. A transgenic mouse strain with antigen-specific T cells (RAG1KO/sf/OVA) demonstrates that the scurfy (sf) mutation causes a defect in T-cell tolerization.
Zahorsky-Reeves JL; Wilkinson JE
Comp Med; 2002 Feb; 52(1):58-62. PubMed ID: 11900414
[TBL] [Abstract][Full Text] [Related]
9. The role of CTLA-4 in regulating Th2 differentiation.
Oosterwegel MA; Mandelbrot DA; Boyd SD; Lorsbach RB; Jarrett DY; Abbas AK; Sharpe AH
J Immunol; 1999 Sep; 163(5):2634-9. PubMed ID: 10453003
[TBL] [Abstract][Full Text] [Related]
10. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing.
Bolling SF; Lin H; Wei RQ; Turka LA
J Heart Lung Transplant; 1996 Sep; 15(9):928-35. PubMed ID: 8889989
[TBL] [Abstract][Full Text] [Related]
11. Re-establishing peripheral tolerance in the absence of CTLA-4: complementation by wild-type T cells points to an indirect role for CTLA-4.
Tivol EA; Gorski J
J Immunol; 2002 Aug; 169(4):1852-8. PubMed ID: 12165509
[TBL] [Abstract][Full Text] [Related]
12. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis.
McIntosh KR; Linsley PS; Drachman DB
Cell Immunol; 1995 Nov; 166(1):103-12. PubMed ID: 7585970
[TBL] [Abstract][Full Text] [Related]
14. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses.
Onodera K; Chandraker A; Schaub M; Stadlbauer TH; Korom S; Peach R; Linsley PS; Sayegh MH; Kupiec-Weglinski JW
J Immunol; 1997 Aug; 159(4):1711-7. PubMed ID: 9257832
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro.
Takayama T; Morelli AE; Robbins PD; Tahara H; Thomson AW
Gene Ther; 2000 Aug; 7(15):1265-73. PubMed ID: 10918497
[TBL] [Abstract][Full Text] [Related]
16. Expression and functional significance of CTLA-4, a negative regulator of T cell activation.
Kosmaczewska A; Ciszak L; Boćko D; Frydecka I
Arch Immunol Ther Exp (Warsz); 2001; 49(1):39-46. PubMed ID: 11266089
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
Via CS; Rus V; Nguyen P; Linsley P; Gause WC
J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
[TBL] [Abstract][Full Text] [Related]
18. CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/Th2 subsets in a murine model of asthma.
Padrid PA; Mathur M; Li X; Herrmann K; Qin Y; Cattamanchi A; Weinstock J; Elliott D; Sperling AI; Bluestone JA
Am J Respir Cell Mol Biol; 1998 Apr; 18(4):453-62. PubMed ID: 9533932
[TBL] [Abstract][Full Text] [Related]
19. Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease.
Chikuma S; Bluestone JA
Eur J Immunol; 2007 May; 37(5):1285-9. PubMed ID: 17429849
[TBL] [Abstract][Full Text] [Related]
20. Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand.
Tang A; Judge TA; Nickoloff BJ; Turka LA
J Immunol; 1996 Jul; 157(1):117-25. PubMed ID: 8683104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
